EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
KR101833589B1
(en)
|
2012-02-24 |
2018-03-02 |
프레드 헛친슨 켄서 리서치 센터 |
Compositions and methods for the treatment of hemoglobinopathies
|
PT3241902T
(en)
|
2012-05-25 |
2018-05-28 |
Univ California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
CA2882499C
(en)
|
2012-08-29 |
2023-09-26 |
Sangamo Biosciences, Inc. |
Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto
|
JP6542124B2
(en)
|
2012-11-27 |
2019-07-10 |
ザ チルドレンズ メディカル センター コーポレーション |
Targeting of the BCL11A distal regulatory element for reinduction of fetal hemoglobin
|
EP3138909A1
(en)
|
2012-12-06 |
2017-03-08 |
Sigma-Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
US20140179770A1
(en)
|
2012-12-12 |
2014-06-26 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
WO2014099744A1
(en)
|
2012-12-17 |
2014-06-26 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
US10138509B2
(en)
|
2013-03-12 |
2018-11-27 |
President And Fellows Of Harvard College |
Method for generating a three-dimensional nucleic acid containing matrix
|
EP2971167B1
(en)
|
2013-03-14 |
2019-07-31 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
US10119133B2
(en)
|
2013-03-15 |
2018-11-06 |
The General Hospital Corporation |
Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
WO2014186585A2
(en)
*
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
CN114015726A
(en)
|
2013-06-17 |
2022-02-08 |
布罗德研究所有限公司 |
Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases with viral components
|
MX2015017311A
(en)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells.
|
BR112015031608A2
(en)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
APPLICATION AND USE OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGETING AND THERAPY
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
WO2015006498A2
(en)
*
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
WO2015006294A2
(en)
|
2013-07-10 |
2015-01-15 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
US11306328B2
(en)
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
ES2670983T3
(en)
|
2013-11-07 |
2018-06-04 |
Editas Medicine, Inc. |
Methods and compositions related to CRISPR with rRNA guiding
|
RS58671B1
(en)
|
2013-11-13 |
2019-06-28 |
Childrens Medical Center |
Nuclease-mediated regulation of gene expression
|
JP2016537028A
(en)
*
|
2013-11-18 |
2016-12-01 |
クリスパー セラピューティクス アーゲー |
CRISPR-CAS System Materials and Methods
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
EP3089989B1
(en)
*
|
2013-12-31 |
2020-06-24 |
The Regents of The University of California |
Cas9 crystals and methods of use thereof
|
CN106133141B
(en)
*
|
2014-01-08 |
2021-08-20 |
哈佛学院董事及会员团体 |
RNA-guided gene driving
|
CN113215219A
(en)
|
2014-02-13 |
2021-08-06 |
宝生物工程(美国) 有限公司 |
Methods of depleting target molecules from an initial collection of nucleic acids, and compositions and kits for practicing same
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
WO2015148860A1
(en)
*
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
WO2015148863A2
(en)
*
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
CN112063586A
(en)
*
|
2014-03-26 |
2020-12-11 |
布里格姆及妇女医院股份有限公司 |
Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
|
EP3134130B1
(en)
|
2014-04-25 |
2019-06-12 |
Children's Medical Center Corporation |
Compositions and methods to treating hemoglobinopathies
|
EP4079847A1
(en)
|
2014-07-30 |
2022-10-26 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
WO2016025759A1
(en)
*
|
2014-08-14 |
2016-02-18 |
Shen Yuelei |
Dna knock-in system
|
MX2017002935A
(en)
|
2014-09-07 |
2017-05-30 |
Selecta Biosciences Inc |
Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses.
|
PT3194570T
(en)
*
|
2014-09-16 |
2021-08-06 |
Sangamo Therapeutics Inc |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
US10370673B2
(en)
|
2014-09-26 |
2019-08-06 |
Purecircle Sdn Bhd |
Single nucleotide polymorphism (SNP) markers for stevia
|
KR102629128B1
(en)
|
2014-12-03 |
2024-01-25 |
애질런트 테크놀로지스, 인크. |
Guide rna with chemical modifications
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EP3237615B2
(en)
|
2014-12-24 |
2023-07-26 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
CN107429230B
(en)
|
2015-01-26 |
2021-11-12 |
菲特治疗公司 |
Methods and compositions for inducing hematopoietic cell differentiation
|
WO2016135559A2
(en)
*
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
AU2016225178B2
(en)
*
|
2015-02-23 |
2022-05-05 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
AU2016246450B2
(en)
|
2015-04-06 |
2022-03-17 |
Agilent Technologies, Inc. |
Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation
|
US10155938B2
(en)
*
|
2015-04-14 |
2018-12-18 |
City Of Hope |
Coexpression of CAS9 and TREX2 for targeted mutagenesis
|
CN104805118A
(en)
*
|
2015-04-22 |
2015-07-29 |
扬州大学 |
Method for targeted knockout of specific gene of Suqin yellow chicken embryonic stem cell
|
US11845928B2
(en)
*
|
2015-05-04 |
2023-12-19 |
Tsinghua University |
Methods and kits for fragmenting DNA
|
EP3294873B1
(en)
*
|
2015-05-08 |
2020-08-19 |
The Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
US11390884B2
(en)
|
2015-05-11 |
2022-07-19 |
Editas Medicine, Inc. |
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
CA2989858A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
US11643668B2
(en)
|
2015-06-17 |
2023-05-09 |
The Uab Research Foundation |
CRISPR/Cas9 complex for genomic editing
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CN108350449B
(en)
|
2015-08-28 |
2022-05-31 |
通用医疗公司 |
Engineered CRISPR-Cas9 nuclease
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9897378B2
(en)
|
2015-10-08 |
2018-02-20 |
Nyc Designed Inspirations Llc |
Cosmetic makeup sponge/blender container
|
CN108513575A
(en)
|
2015-10-23 |
2018-09-07 |
哈佛大学的校长及成员们 |
Nucleobase editing machine and application thereof
|
US20180325947A1
(en)
*
|
2015-10-27 |
2018-11-15 |
Children's Hospital Medical Center |
Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
|
MX2018005611A
(en)
|
2015-11-03 |
2018-11-09 |
Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix.
|
US20180273609A1
(en)
*
|
2015-11-04 |
2018-09-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
EP4249074A3
(en)
|
2015-11-04 |
2024-01-10 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
EP3371301A4
(en)
|
2015-11-04 |
2019-06-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
IL308706A
(en)
*
|
2015-12-28 |
2024-01-01 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
PT3408382T
(en)
|
2016-01-27 |
2022-06-27 |
Oncorus Inc |
Oncolytic viral vectors and uses thereof
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
US20200255857A1
(en)
*
|
2016-03-14 |
2020-08-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
EP3445388A2
(en)
*
|
2016-04-18 |
2019-02-27 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hemoglobinopathies
|
WO2017189525A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
WO2017191503A1
(en)
*
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
CA3031785A1
(en)
*
|
2016-07-25 |
2018-02-01 |
Bluebird Bio, Inc. |
Bcl11a homing endonuclease variants, compositions, and methods of use
|
KR20230095129A
(en)
|
2016-08-03 |
2023-06-28 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
EP3497214B1
(en)
|
2016-08-09 |
2023-06-28 |
President and Fellows of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
CN106244555A
(en)
*
|
2016-08-23 |
2016-12-21 |
广州医科大学附属第三医院 |
A kind of method of efficiency improving gene targeting and the base in-situ remediation method in beta globin gene site
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
EP4248979A3
(en)
*
|
2016-09-08 |
2023-12-20 |
2seventy bio, Inc. |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
AU2018212854A1
(en)
|
2017-01-27 |
2019-08-01 |
Children's Hospital Medical Center |
Methods of enhancing engraftment activity of hematopoietic stem cells
|
TW201839136A
(en)
*
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(en)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Base-editing factor from cytosine to guanine
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
US11268082B2
(en)
|
2017-03-23 |
2022-03-08 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
EP3615664A4
(en)
*
|
2017-04-24 |
2021-01-27 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Homology directed repair compositions for the treatment of hemoglobinopathies
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
WO2018218135A1
(en)
|
2017-05-25 |
2018-11-29 |
The Children's Medical Center Corporation |
Bcl11a guide delivery
|
WO2018218166A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
WO2018220210A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
AU2018306455A1
(en)
|
2017-07-26 |
2020-02-27 |
Virogin Biotech Canada Ltd |
Oncolytic viral vectors and uses thereof
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
Pcsk9 endonuclease variants, compositions, and methods of use
|
KR20200086670A
(en)
|
2017-10-13 |
2020-07-17 |
셀렉타 바이오사이언시즈, 인크. |
Methods and compositions for attenuating antiviral delivery vector IgM responses
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
US20210180091A1
(en)
*
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
CN109722415B
(en)
*
|
2017-10-27 |
2021-01-26 |
博雅辑因(北京)生物科技有限公司 |
Hematopoietic stem cell culture composition, culture medium and hematopoietic stem cell culture method
|
WO2019113149A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Crispr Therapeutics Ag |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
EP3749767A1
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
EP3749768A1
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US10968257B2
(en)
|
2018-04-03 |
2021-04-06 |
The Broad Institute, Inc. |
Target recognition motifs and uses thereof
|
AU2019260754A1
(en)
*
|
2018-04-27 |
2020-11-26 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
|
US20200102563A1
(en)
*
|
2018-10-02 |
2020-04-02 |
Exosome Therapeutics, Inc. |
Exosome loaded therapeutics for treating sickle cell disease
|
KR20210102925A
(en)
*
|
2018-12-10 |
2021-08-20 |
블루버드 바이오, 인코포레이티드. |
Homing Endonuclease Variants
|
EP3898958A1
(en)
|
2018-12-17 |
2021-10-27 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
CA3128755A1
(en)
*
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
WO2020191249A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
CN110042124A
(en)
*
|
2019-04-25 |
2019-07-23 |
国家卫生健康委科学技术研究所 |
Genome base editor increases the kit of fetal hemoglobin level and application in human red blood cells
|
CN111939271A
(en)
*
|
2019-04-30 |
2020-11-17 |
博雅辑因(北京)生物科技有限公司 |
Method for predicting treatment effectiveness of hemoglobinopathy
|
EA202192931A1
(en)
*
|
2019-04-30 |
2022-02-22 |
Эдиджен Инк. |
METHOD FOR PREDICTION OF THE EFFICIENCY OF HEMOGLOBINOPATHY TREATMENT
|
AU2020284555A1
(en)
|
2019-05-28 |
2021-12-23 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
CN114072518A
(en)
*
|
2019-06-28 |
2022-02-18 |
Asc治疗公司 |
Methods and compositions for treating thalassemia or sickle cell disease
|
AU2020358863A1
(en)
|
2019-10-03 |
2022-05-12 |
Artisan Development Labs, Inc. |
CRISPR systems with engineered dual guide nucleic acids
|
EP4058586A4
(en)
*
|
2019-11-15 |
2024-04-10 |
Univ Leland Stanford Junior |
Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
|
CN112979823B
(en)
*
|
2019-12-18 |
2022-04-08 |
华东师范大学 |
Product and fusion protein for treating and/or preventing beta-hemoglobinopathy
|
DE112021002672T5
(en)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
|
EP4150081A1
(en)
*
|
2020-05-13 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of betahemoglobinopathies
|
EP4262850A1
(en)
*
|
2020-12-21 |
2023-10-25 |
2seventy bio, Inc. |
Compositions and methods for site-directed mutagenesis
|
EP4304633A1
(en)
|
2021-03-12 |
2024-01-17 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
CN113481184A
(en)
*
|
2021-08-06 |
2021-10-08 |
北京大学 |
Fusion proteins and methods of use thereof
|
CA3230927A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
CN114457119B
(en)
*
|
2022-04-11 |
2022-08-12 |
中吉智药(南京)生物技术有限公司 |
Application of lentiviral vector in preparation of drug for treating beta-thalassemia
|
EP4273242A1
(en)
*
|
2022-05-03 |
2023-11-08 |
ETH Zurich |
Crispr-based modification of human hbd gene
|